**DOCUMENT NUMBER:** APBMT-COMM-042

**DOCUMENT TITLE:**
Monitoring Late Effects for APBMT Patients

**DOCUMENT NOTES:**

---

### Document Information

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision</td>
<td>04</td>
</tr>
<tr>
<td>Vault</td>
<td>APBMT-Common-rel</td>
</tr>
<tr>
<td>Status</td>
<td>Release</td>
</tr>
<tr>
<td>Document Type</td>
<td>APBMT</td>
</tr>
</tbody>
</table>

### Date Information

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creation Date</td>
<td>30 Apr 2021</td>
</tr>
<tr>
<td>Release Date</td>
<td>19 May 2021</td>
</tr>
<tr>
<td>Effective Date</td>
<td>19 May 2021</td>
</tr>
<tr>
<td>Expiration Date</td>
<td></td>
</tr>
</tbody>
</table>

### Control Information

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author</td>
<td>MOORE171</td>
</tr>
<tr>
<td>Owner</td>
<td>JLF29</td>
</tr>
<tr>
<td>Previous Number</td>
<td>APBMT-COMM-042 Rev 03</td>
</tr>
<tr>
<td>Change Number</td>
<td>APBMT-CCR-201</td>
</tr>
</tbody>
</table>
APBMT-COMM-042
MONITORING LATE EFFECTS FOR APBMT PATIENTS

1 PURPOSE
1.1 To describe the monitoring for late effects in Adult and Pediatric Blood and Marrow Transplant (APBMT) patients.

2 INTRODUCTION
2.1 Advances in hematopoietic stem cell transplantation techniques and supportive care have led to progressive improvements in long-term survival for patients undergoing hematopoietic stem cell transplantation. These patients are at risk for developing late complications related to pre, peri, and post-transplant exposures and require screening and preventative practices to maximize their overall health and quality of life.

3 SCOPE AND RESPONSIBILITIES
3.1 All recipients of hematopoietic stem cell transplant are at risk for developing late transplant complications.
3.2 Pediatric patients, in particular, are at risk for complications affecting developing organs and growth and development.
3.3 Physician, nurses, and advanced practice providers are responsible for ensuring that proper monitoring for follow up care is completed by appropriate specialist.

4 DEFINITIONS/ACRONYMS
4.1 APBMT Adult and Pediatric Blood and Marrow Transplant
4.2 HSCT Hematopoietic Stem Cell Transplant
4.3 GVHD Graft versus Host Disease
4.4 TBI Total Body Irradiation

5 MATERIALS
5.1 N/A

6 EQUIPMENT
6.1 N/A

7 SAFETY
7.1 N/A

8 PROCEDURE
8.1 Patients are encouraged to be evaluated by a medical profession at least annually for post-transplant follow up care. Ideally, the patient should be seen by a transplant team.
8.1.1 The pediatric program has established a survivorship clinic focused on the evaluation and treatment of patients at risk for developing complications and/or late effects related to their therapy. Patients will be offered coordinated care through this clinic as an extension of their transplant course.

8.2 During an annual evaluation, the physician led team completes an age appropriate comprehensive review of systems and physical exam with a focus on late effects and post-transplant complications related to the following organ/tissue systems:

8.2.1 Immune System
  8.2.1.1 Infections
  8.2.1.2 Hypogammaglobinemia
  8.2.1.3 T-cell function
  8.2.1.4 Immunizations

8.2.2 Hematologic system
  8.2.2.1 Anemia
  8.2.2.2 Thrombocytopenia
  8.2.2.3 Neutropenia
  8.2.2.4 Lymphopenia
  8.2.2.5 MCV
  8.2.2.6 Iron overload (ferritin, Fe/TIBC)

8.2.3 Ocular
  8.2.3.1 Cataracts
  8.2.3.2 Sicca syndrome
  8.2.3.3 Microvascular retinopathy
  8.2.3.4 Optic nerve integrity
  8.2.3.5 Visual Acuity
  8.2.3.6 Graft Versus Host Disease (GVHD)

8.2.4 Oral
  8.2.4.1 Sicca syndrome
  8.2.4.2 Dental caries
  8.2.4.3 Tooth agenesis
  8.2.4.4 Enamel dysplasia
  8.2.4.5 Oral cancer (especially squamous cell cancers)
  8.2.4.6 GVHD
8.2.5 Respiratory System
8.2.5.1 Idiopathic pneumonia syndrome
8.2.5.2 Bronchiolitis obliterans syndrome
8.2.5.3 Bronchiectasis
8.2.5.4 Cryptogenic organizing pneumonia
8.2.5.5 Sino-pulmonary infections
8.2.5.6 GVHD

8.2.6 Cardiac and Vascular System
8.2.6.1 Cardiomyopathy
8.2.6.2 Congestive heart failure
8.2.6.3 Arrhythmias
8.2.6.4 Valvular anomalies
8.2.6.5 Coronary artery disease
8.2.6.6 Cerebrovascular disease
8.2.6.7 Peripheral arterial disease
8.2.6.8 Hypertension
8.2.6.9 Hyperlipidemia

8.2.7 Gastrointestinal
8.2.7.1 Esophageal stricture(s)
8.2.7.2 Secondary malignancies

8.2.8 Liver
8.2.8.1 Hepatitis B
8.2.8.2 Hepatitis C
8.2.8.3 Iron Overload
8.2.8.4 Cirrhosis
8.2.8.5 GVHD

8.2.9 Renal and Genitourinary System
8.2.9.1 Chronic kidney disease
8.2.9.2 Bladder dysfunction
8.2.9.3 Urinary tract infections
8.2.9.4 Hypertension
8.2.9.5 Vaginal stenosis
8.2.9.6 Vaginal cervical, ovarian and uterine cancers
8.2.10 Muscle and Connective Tissue
  8.2.10.1 Myopathy
  8.2.10.2 Fasciitis/scleroderma
  8.2.10.3 Polymyositis
  8.2.10.4 Joint Contractures
  8.2.10.5 Chronic arthritis
  8.2.10.6 GVHD

8.2.11 Skeletal
  8.2.11.1 Osteopenia/osteoporosis
  8.2.11.2 Avascular necrosis
  8.2.11.3 Short stature
  8.2.11.4 Growth failure

8.2.12 Nervous System
  8.2.12.1 Leukoencephalopathy
  8.2.12.2 Late infections
  8.2.12.3 Neuropsychological deficits
  8.2.12.4 Cognitive deficits
  8.2.12.5 Calcineurin neurotoxicity
  8.2.12.6 Peripheral neuropathy
  8.2.12.7 Chronic pain
  8.2.12.8 Secondary malignancies

8.2.13 Endocrine
  8.2.13.1 Hypopituitarism
  8.2.13.2 Thyroid problems
  8.2.13.3 Central adrenal insufficiency
  8.2.13.4 Hypogonadism or precocious puberty
  8.2.13.5 Growth hormone failure
  8.2.13.6 Infertility

8.2.14 Mucocutaneous
  8.2.14.1 Cutaneous sclerosis
  8.2.14.2 Squamous cell carcinoma
  8.2.14.3 Genital GVHD
8.2.15 Psychosocial Distress
   8.2.15.1 Depression
   8.2.15.2 Anxiety
   8.2.15.3 Fatigue
   8.2.15.4 Sexual dysfunction

8.2.16 Secondary Malignancies
   8.2.16.1 AML/MDS
   8.2.16.2 Sarcomas

8.2.17 General Health

8.3 If a late effect is identified, the patient should be referred to and be treated by an appropriate specialist.

8.4 During the annual assessment the team may also screen for recurrence of primary cancer or the development of any secondary cancers.

8.5 During the annual assessment, the team will document:
   8.5.1 GVHD
   8.5.2 Chimerism (for allogeneic transplants)
   8.5.3 Immune Reconstitution until normal and patient is re-immunized

8.6 During the annual assessment, for patients over the age of 18, the team will advise the patient regarding:
   8.6.1 Education/Career
   8.6.2 Health insurance
   8.6.3 Immunizations
   8.6.4 Smoking
   8.6.5 Alcohol consumption
   8.6.6 Diet and physical exercise
   8.6.7 Sun exposure
   8.6.8 Cancer Screening
   8.6.9 Mammograms Age 25
   8.6.10 Colonoscopy Age 30
   8.6.11 Prostate screening

8.7 During the annual assessment for pediatric patients, the team will advise the patient and caregiver regarding:
   8.7.1 School Performance
   8.7.2 Growth
   8.7.3 Pubertal development
8.7.4 Dental issues
8.7.5 Cataract screening
8.7.6 Thyroid screening (if patient received Total Body Irradiation (TBI))

8.8 If deemed necessary, patients under the care of the pediatric transplant care team will be considered for transition to adult care. At such time, the pediatric team will consult with the adult care team to coordinate transition of care. Copies of all relevant health information will be provided to the accepting health care team to ensure continuity of care and will include, but is not limited, to a summary of the patient’s past medical history, pre-transplant workup, conditioning, transplant, engraftment status, and post-transplant course to date.

9 RELATED DOCUMENTS/FORMS
9.1 Adult patients attend a provider led discharge education class. Slides for that presentation are updated regularly based on evidence based practice and process.
9.2 Pediatric patients/caregivers are given a Discharge Handbook as well as attend discharge classes held by PBMT Discharge Planner.
9.3 Be The Match® After Transplant Care Toolkit (print copy with instructions for mobile application).

10 REFERENCES

11 REVISION HISTORY

<table>
<thead>
<tr>
<th>Revision No.</th>
<th>Author</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>04</td>
<td>McCollum</td>
<td>Section 8.2.1 updated to include Immunizations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.2.2 – new section added (hematologic)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.2.7 – added secondary malignancies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.2.12 – added chronic pain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.2.13 added hypopituitarism, thyroid problems, central adrenal insufficient, precocious puberty, growth hormone failure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.2.14 REMOVED sarcomyelia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.2.16 – new section for secondary malignancies</td>
</tr>
<tr>
<td>Revision No.</td>
<td>Author</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
<td>--------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.5 – updated immune reconstitution verbiage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.6- added education/career, health insurance, diet and exercise, sun exposure, mammogram age 25, colonoscopy age 30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Throughout- “physician led team“ transitioned to “team”</td>
</tr>
</tbody>
</table>
# Signature Manifest

**Document Number:** APBMT-COMM-042  
**Title:** Monitoring Late Effects for APBMT Patients  
**Effective Date:** 19 May 2021

All dates and times are in Eastern Time.

## APBMT-COMM-042 Monitoring Late Effects for APBMT Patients

### Author

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sally McCollum (MOORE171)</td>
<td></td>
<td>30 Apr 2021, 09:34:27 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Management

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelson Chao (CHAO0002)</td>
<td></td>
<td>30 Apr 2021, 09:54:57 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Medical Director

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Kurtzberg (KURTZ001)</td>
<td></td>
<td>30 Apr 2021, 10:33:40 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Quality

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bing Shen (BS76)</td>
<td></td>
<td>03 May 2021, 12:53:28 PM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

### Document Release

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betsy Jordan (BJ42)</td>
<td></td>
<td>04 May 2021, 10:28:23 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>